Renascience Begins Phase I Clinical Trials in Saudi Arabia

TOKYO, Jul 21 (Pulse News Wire) – Renascience Inc. (4889.T) announced the commencement of Phase I clinical trials for RS5,614 at the King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia.

The trial, aimed at evaluating safety and tolerability, includes exploratory biological assessments and is scheduled to conclude by December 2026. Key details of the study include: - Conducted by KAIMRC in Saudi Arabia - Principal Investigator: Dr.

Raneem Milyani, Consultant and Director of Geriatric and Internal Medicine - Expected completion by December 31, 2026, followed by final report compilation This Phase I trial follows a Memorandum of Understanding signed with KAIMRC on October 6, 2025, which outlined collaboration on clinical development and joint research for anti-aging treatments. Based on the results, plans are underway to conduct a Phase II trial focused on assessing anti-aging effects.

Regarding potential impact on performance, Renascience considers the immediate effect to be minor but commits to disclosing any significant developments promptly.